Skip to main content
SpringerLink
Log in

Onkologie ’96

  • Update
  • Published:
Medizinische Klinik Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Al-Sarraf, M., M. LeBlanc, P. G. S. Giri, K. Fu, J. Cooper, T. Vuong, A. Forastiere, G. Adams, W. Sakr, D. Schuller, J. Ensley: Superiority of chemo-radiotherapy (CT-RT) vs. radiotherapy (RT) in patients (PTS) with locally advanced nasopharyngeal cancer (NPC). Preliminary results of intergroup (0099) (SWOG 8892. RTOG 8817, ECOG 2388) randomized study. Proc. ASCO 15 (1996), Nr. 882.

    Google Scholar 

  2. Albain, K. S., V. W. Rusch, J. J., Crowley, T. W. Rice, A. T. Turrisi III, J. K. Weick, V. A. Lonchyna, C. A. Presant, R. J. McKenna, D. R. Gandara, H. Fosmire, S. A. Taylor, K. J. Stelzer, K. R. Beasley, R. B. Livingston: Concurrent Cisplatin/Etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group Phase II Study 8805. J. clin. Oncol. 13 (1995), 1880–1892.

    PubMed  CAS  Google Scholar 

  3. Allan, N. C., S. M. Richards, P. C. A., Shepherd, on be-half of the UK Medical Research Councils Working Parties for Therapeutic Trials in Adult Leukaemia: UK Medical Research Council Randomised. Multicentre Trial of Interferon-αn 1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 345 (1995), 1392–1397.

    Article  PubMed  CAS  Google Scholar 

  4. Allen-Mersh, T. G., S. Earlam, C. Fordy, K. Abrams, J. Houghton: Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 344 (1994), 1255–1260.

    Article  PubMed  CAS  Google Scholar 

  5. Anderson, J. E., F. R. Appelbaum, G. Schoch, T. Gooley, C. Anasetti, W. I. Bensinger, E. Bryant, C. D. Buckner, T. Chauncey, R. A. Clift, H. J. Deeg, K. Doney, M. Flowers, J. A. Hansen, P. J. Martin, D. C. Matthews, R. A. Nash, J. E. Sanders, H. Shulman, K. M. Sullivan, R. P. Witherspoon, R. Storb: Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J. clin. Oncol. 14 (1996), 220–226.

    PubMed  CAS  Google Scholar 

  6. Arriagada, R., L. E. Rutqvist, A. Mattsson, A. Kramar, S. Rotstein: Adequate locoregional treatment for early breast cancer may prevent secondary dissemination. J. clin. Oncol. 13 (1995), 2869–2878.

    PubMed  CAS  Google Scholar 

  7. Arriagada, R., T. Le Chevalier, F. Borie, A. Rivière, P. Chomy, I. Monnet, A. Tardivon, F. Viader, M. Tarayre, S. Benhamou: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J. nat. Cancer Inst. 87 (1995), 183–190.

    Article  PubMed  CAS  Google Scholar 

  8. Attal, M., J.-L. Harouseau, A.-M. Stoppa, J.-J. Sotto, J.-G. Fuzibet, J.-F. Rossi, P. Casassus, H. Maisonneuve, T. Facon, N. Ifrah, C. Payen, R. Bataille, for the Intergroupe Francais du Myélome: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New Engl. J. Med. 335 (1996), 91–97.

    Article  PubMed  CAS  Google Scholar 

  9. Atzpodien J., E. L. Hänninen, H. Kirchner, H. Bodenstein, M. Pfreundschuh, U. Rebmann, B. Metzner, H.-J. Illiger, G. Jakse, T. Niesel, H.-J. Scholz, S. Wilhelm, T. Pielmeier, G. Zakrzewski, G. Blum, J. Beier, G.-W. Müller, S. Duensing, P. Anton, E. Allhoff, U. Jonas, H. Poliwoda: Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alpha-2 in progressive metastatic renal cell carcinoma. J. clin. Oncol. 13 (1995), 497–501.

    PubMed  CAS  Google Scholar 

  10. Baniel, J., R. S. Foster, R. Gonin, J. E. Messemer, J. P. Donohue, L. H. Einhorn: Late relapse of testicular cancer. J. clin. Oncol. 13 (1995), 1170–1176.

    PubMed  CAS  Google Scholar 

  11. Bartlett, N. L., S. A. Rosenberg, R. T. Hoppe, S. L. Hancock, S. J. Horning: Brief chemotherapy, Stanford V. and adjuvant radiotherapy for bulky or advancedstage Hodgkin’s disease: A preliminary report. J. clin. Oncol. 13 (1995), 1080–1088.

    PubMed  CAS  Google Scholar 

  12. Baselga, J., D. Tripathy, J. Mendelsohn, S. Baughman, C. C. Benz, L. Dantis, N. T. Sklarin, A. D. Seidman, C. A. Hudis, J. Moore, P. P. Rosen, T. Twaddell, I. C. Henderson, L. Norton: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER/neu-overexpressing metastatic breast cancer. J. clin. Oncol. 14 (1996), 737–744.

    PubMed  CAS  Google Scholar 

  13. Bates, B. A., F. C. Detterbeck, S. A. Bemard, B. F. Qaqish, J. E. Tepper: Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. J. clin. Oncol. 14 (1996), 156–163.

    PubMed  CAS  Google Scholar 

  14. Bayerdörffer, E., A. Neubauer, B. Rudolph, C. Thiede, N. Lehn, S. Eidt, M. Stolte, for MALT-Lymphoma Study Group: Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of helicobacter pylori infection. Lancet 345 (1995) 1591–1593.

    Article  PubMed  Google Scholar 

  15. Berenson, J. R., A. Lichtenstein, L. Porter, M. A. Dimopoulos, R. Bordoni, S. George, H. A. Blacklock, O. Ballester, M. J. Kovacs, D. J. Reitsmau, M. Heffernan, J. Seaman, R. D. Knight, for the Myeloma Aredia Study Group: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. New Engl. J. Med. 334 (1996), 488–493.

    Article  PubMed  CAS  Google Scholar 

  16. Bezwoda, W. R., L. Seymour, R. D. Dansey: High-dose-chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J. clin. Oncol. 13 (1995), 2483–2489.

    PubMed  CAS  Google Scholar 

  17. Bieling, P., N. Rehan, P. Winkler, K. Helmke, R. Maas, N. Fuchs, S. Bielack, U. Heise, H. Jürgens, J. Treuner, R. Romanowski, U. Exner, R. Kotz, K. Winkler: Tumor size and prognosis in aggressively treated osteosarcoma. J. clin. Oncol. 14 (1996), 848–858.

    PubMed  CAS  Google Scholar 

  18. Bishop, M. R., P. L. Iversen, E. Bayever, J. G. Sharp, T. C. Greiner, B. L. Copple, R. Ruddon, G. Zon, J. Spinolo, M. Arneson, J. O. Armitage, A. Kessinger: Phase 1 trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J. clin. Oncol. 14 (1996), 1320–1326.

    PubMed  CAS  Google Scholar 

  19. Bishop, J. F., J. P. Matthews, G. A. Young, J. Szer, A. Gillet, D. Joshua, K. Bradstock, A. Enno, M. M. Wolf, R. Fox, R. Cobcroft, R. Hermann, M. Van Der Weyden, R. M. Löwenthal, F. Page, O. M. Garson, S. Juneja: A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87 (1996), 1710–1717.

    PubMed  CAS  Google Scholar 

  20. Bokemeyer, C., H.-J. Schmoll: Treatment of testicular cancer and the development of secondary malignancies. J. clin. Oncol. 13 (1995), 283–292.

    PubMed  CAS  Google Scholar 

  21. Bonadonna G., P. Valagussa, A. Moliterni, M. Zambetti, C. Bramsbilla: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. New Engl. J. Med. 332 (1995), 901–906.

    Article  PubMed  CAS  Google Scholar 

  22. Bonenkamp, J. J., I. Songun, J. Hermans, M. Sasako, K. Welvaart, J. T. M. Plukker, P. van Elk, H. Obertop, P. W. Gouma, C. W. Taat, J. van Lanschot, S. Meyer, P. W. de Graaf, M. F. von Meyenfeldt, H. Tilanus, C. J. H. van de Velde: Randomised comparison of morbidity after D1 and D2 dissektion for gastric cancer in 996 Dutch patients. Lancet 345 (1995), 745–748.

    Article  PubMed  CAS  Google Scholar 

  23. Bonomi, P., K. Kim, A. Chang, D. Johnson: Phase III trial comparing Etoposide (E) Cisplatin (C) versus Taxol (T) with Cisplatin-G-CSF (G) versus Taxol-Cisplatin in advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group (ECOG) Trial. Proc. ASCO 15 (1996), Nr. 382.

    Google Scholar 

  24. Browman, G. P., D. Bergsagel, D. Sicheri, S. O’Reilly, K. S. Wilson, S. Rubin, A. Belch, C. Shustik, R. Barr, I. Walker, K. James, B. Zee, D. Johnston: Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J. clin. Oncol. 13 (1995), 2354–2360.

    PubMed  CAS  Google Scholar 

  25. Bunt, A. M. G., J. Hermans, V. T. H. B. M. Smit, C. J. H. van de Velde, G. J. Fleuren, J. A. Bruijn: Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and western countries. J. clin. Oncol. 13 (1995), 19–25.

    PubMed  CAS  Google Scholar 

  26. Burkes, R. L., F. A. Shepherd: Gemcitabine in the treatment of non-small-cell lung cancer. Ann. Oncol. 6, Suppl. 3 (1995), S57-S60.

    PubMed  Google Scholar 

  27. Buzdar, A., W. Jonat, A. Howell, S. E. Jones, C. Blomqvist, C. L. Vogel, W. Eiermann, J. M. Wolter, M. Azab, A. Webster, P. V. Plourde for the Arimidex Study Group: Anastrozole, a potent and selective aromatase inhibitor versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J. clin. Oncol. 14 (1996), 2000–2011.

    PubMed  CAS  Google Scholar 

  28. Cahn, J. Y., M. Labopin, F. Mandelli, A. H. Goldstone, K. Eberhardt, J. Reiffers, A. Ferrant, I. Franklin, P. Hervé, A. Gratwohl, N. C. Gorin: Autologous bone marrow transplantation for first remission acute myeloblastic leukemia in patients older than 50 years: a retrospective analysis of the European Bone Marrow Transplant Group. Blood 85 (1995), 575–579.

    PubMed  CAS  Google Scholar 

  29. Cairncross, G., D. macdonald, S. Ludwin, D. Lee, T. Cascino, J. Buckner, D. Fulton, E. Dropcho, D. Stewart, C. Schold Jr, N. Wainman, E. Eisenhauer for the National Cancer Institute of Canda Clincal Trials Group: Chemotherapy for anaplastic oligodendroglioma. J. clin. Oncol. 12 (1994), 2013–2021.

    PubMed  CAS  Google Scholar 

  30. Canevari S., G. Stoter, F. Arienti, G. Bolis, M. I. Colnaghi, E. M. Di Re, A. M. M. Eggermont, S. H. Goey, J. W. Gratama, C. H. J. Lamers, M. A. Nooy, G. Parmiani, F. Raspagliesi, F. Ravagnani, G. Scarfone, J. B. Trimbos, S. O. Warnaar, R. L. H. Bolhuis: Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J. nat. Cancer Inst. 87 (1995), 1463–1469.

    Article  PubMed  CAS  Google Scholar 

  31. Carmichael, J., U. Fink, R. C. G. Rusell, M. F. Spittle, A. L. Harris, G. Spiessi, J. Blatter: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Brit. J. Cancer 73 (1996), 101–105.

    PubMed  CAS  Google Scholar 

  32. Carpenter, C. C. J., M. A. Fischl, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. G. Montaner, D. D. Richman, M. S. Saag, R. T. Schooley, M. A. Thompson, S. Vella, P. G. Yeni, P. A. Volberding for the International AIDS Society-USA: Anti retroviral therapy for HIV infection in 1996. Recommendations of an international panel. J. Amer. med. Ass. 276 (1996), 146–154.

    Article  CAS  Google Scholar 

  33. Cedermark B., H. Johansson, L. E. Rutqvist, N. Wilking, for the Stockholm Colorectal Cancer Study Group: The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. Cancer (Philad.) 75 (1995), 2269–2275.

    Article  CAS  Google Scholar 

  34. Chevallier, B., P. Fumoleau, P. Kerbrat, V. Dieras, H. Roche, I. Krakowski, N. Azli, M. Bayssas, M. A. Lentz, M. Van Glabbeke: Doxetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J. clin. Oncol. 13 (1995), 314–322.

    PubMed  CAS  Google Scholar 

  35. Coindre J.-M., P. Terrier, N. B. Bui, F. Bonichon, F. Collin, V. Le Doussal, A.-M. Mandard, M.-O. Vilain, J. Jacquemier, H. Duplay, X. Sastre, C. Barlier, M. Henry-Amar, J. Macé-Lesech, G. Contesso: Prognostic factors in adult patients with locally controlled soft tissue sarcoma: a study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J. clin. Oncol. 14 (1996), 869–877.

    PubMed  CAS  Google Scholar 

  36. Conroy, T., P.-L. Etienne, A. Adenis D. J. T. Wagener, B. Paillot, E. François, L. Bedenne, J.-H. Jacob, J.-F. Seitz, H. Bleiberg, C. Van Pottelsberghe, M. Van Glabbeke, F.-M. Delgado, S. Merle, J. Wils for the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group: Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. J. clin. Oncol. 14 (1996), 164–170.

    PubMed  CAS  Google Scholar 

  37. Conte, P. F., M. Bruzzone, F. Carnino, A. Adduci, R. Algeri, A. Bellini, F. Boccardo, I. Brunetti, E. Catsafados, S. Chiara, G. Foglia, L. Gallo, L. Iskra, S. Mammoliti, G. Parodi, N. Ragni, R. Rosso, S. Rugiati, A. Rubagotti: High-dose verus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. J. clin. Oncol. 14 (1996), 351–356.

    PubMed  CAS  Google Scholar 

  38. Corfu-A Study Group: Phase II randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J. clin. Oncol. 13 (1995), 921–928.

    Google Scholar 

  39. Crump M., P. E. Goss, M. Prince, C. Girouard: Out-come of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. J. clin. Oncol. 14 (1996), 66–69.

    PubMed  CAS  Google Scholar 

  40. Cullen M. H., S. P. Stenning, M. C. Parkinson, S. D. Fossa, S. B. Kaye, A. H. Horwich, S. J. Harland, M. V. Williams, R. Jakes for the Medical Research Council Testicular Tumor Working Part: Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a medical research council report. J. clin. Oncol. 14 (1996), 1106–1113.

    PubMed  CAS  Google Scholar 

  41. Cuschieri A., P. Fayers, J. Fielding, J. Craven, J. Bancewicz, V. Joypaul, P. Cook, for the Surgical Cooperative Group: Postoperative morbidity and mortality after D1 und D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. Lancet 347 (1996) 995–999.

    Article  PubMed  CAS  Google Scholar 

  42. Dagliotti L., A. Berruti, T. Buniva, P. Zola, M. G. Baù, A. Farri, M. G. Sarobba, A. Bottini, P. Alquati, F. Deltetto, P. Gosso, C. M. G. Moro, M. Sussio, D. Perroni: Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial. J. clin. Oncol. 14 (1996), 1165–1172.

    Google Scholar 

  43. Dalton S. W., J. J. Crowley, S. S. Salmon, T. M. Grogan, L. R. Laufman, G. R. Weiss, J. D. Bonnet: A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group Study. Cancer (Philad.) 75 (1995), 815–820.

    Article  CAS  Google Scholar 

  44. Daus H., L. Trümper, B. Bürger, S. Kriener, G. von Blohn, M. Zeitz, M. Pfreundschuh: Ki-ras-Mutation als molekularer Tumormarker für Pankreaskarzinome. Dtsch. med. Wschr. 120 (1995), 821–825.

    PubMed  CAS  Google Scholar 

  45. De Lena, M., P. Ditonno, V. Lorusso, M. Brandi, A. Timurian, F. Marzullo, V. Ventrella, A. Pellecchia: CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin’s lymphoma: A pilot study. J. clin. Oncol. 13 (1995), 953–960.

    PubMed  Google Scholar 

  46. DeAndrés L., J. Brunet, A. López-Pousa, J. Burgués, M. Yega, J. M. Tabernero, R. Mesia, J. J. López: Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV M0 head and neck cancer. J. clin. Oncol. 13 (1995), 1493–1500.

    Google Scholar 

  47. Diehl V., M. Loeffler, M. Pfreundschuh, U. Ruehl, D. Hasenclever, H. Nisters-Backes, M. Sieber, K. Smith, H. Tesch, W. Geilen, M. Adler, H. Bartels, U. Brandenburg, P. Diezler, G. Doelken, J. Enzian, R. Fuchs, W. Gassmann, H. Gerhartz, U. Hagenaukamp, R. Hecht, E. Hiller, H. Hinkelbein, B. Lathan, H. Kirchner, G. Kuehn, H. Kuerten, U. Loos, B. Makoski, W. Oertel, S. Petsch, R. Pfab, H. Pflueger, M. Planker, R. Rohloff, H. Sack, S. Samandari, R. Sauer, K. Schalk, G. Schmitz, W. Schoppe, G. Schwieder, S. Szepesi, J. Teichmann, W. Wilhelmy, P. Worst, R. Fischer, A. Georgii, K. Huebner, E.-W. Schwarze for the German Hodgkin’s Study Group (GHSG): Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin’s disease. Ann. Oncol. 6 (1995), 901–910.

    PubMed  CAS  Google Scholar 

  48. Dreyfuss, I. A., J. R. Clark, C. M. Norris, R. M. Rossi, J. W. Lucarini, P. M. Busse, M. D. Poulin, L. Thorhill, R. Costello, and M. R. Posner: Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J. clin. Oncol. 14 (1996), 1672–1678.

    PubMed  CAS  Google Scholar 

  49. Early Breast Cancer Trialists Collaborative Group: Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. New Engl. J. Med. 333 (1995), 1444–1455.

    Article  Google Scholar 

  50. Eisenhauer, E. A., W. W. ten Bokkel Huinink, K. D. Swenerton, L. Gianni, J. Myles, M. E. L. van der Burg, I. Kerr, J. B. Vermorken, K. Buser, N. Colombo, M. Bacon, P. Santabárbara, N. Onetto, B. Winograd, R. Canetta: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J. clin. Oncol. 12 (1994), 2654–2666.

    PubMed  CAS  Google Scholar 

  51. El-Sayved, S., N. Nelson: Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: a meta-analysis of prospective and randomized trials. J. clin. Oncol. 14 (1996), 838–847.

    Google Scholar 

  52. Farhat, F., S. Culine, C. Théodore, M. Békradda, M.-J. Terrier-Lacombe, J.-P. Droz: Cisplatin and ifosfamide with either vinblastime or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients. Cancer (Philad.) 77 (1996), 1193–1197.

    Article  CAS  Google Scholar 

  53. Fennelly D., J. Schneider, D. Spriggs, C. Bengala, T. Hakes, L. Reich, R. Barakat, J. Curtin, M. A. S. Moore, W. Hoskins, L. Noton, J. Crown: Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. J. clin. Oncol. 13 (1995), 1160–1166.

    PubMed  CAS  Google Scholar 

  54. Fermé C., Y. Bastion, E. Lepage, F. Berger, P. Brice, P. Morel, J. Gabarre, G. Nédellec, O. Reman, N. Chéron, O. Oberlin, B. Coiffier: The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin’s disease. Ann. Oncol. 6 (1995), 543–549.

    PubMed  Google Scholar 

  55. Fink, U., H. J. Stein, C. Schuhmacher, H. J. Wilke: Neoadjuvant chemotherapy for gastric cancer: Update. World J. Surg. 19 (1995), 509–516.

    Article  PubMed  CAS  Google Scholar 

  56. Fisher, B., J. Dignam, E. P. Mamounas, J. P. Constantino, D. L. Wickerham, C. Redmond, N. Wolmark, N. V. Dimitrov, D. M. Bowman, A. G. Glass, J. N. Atkins, N. Abramson, C. M. Sutherland, B. S. Aron, R. G. Margolese: Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from national surgical adjuvant breast and bowel project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J. clin. Oncol. 14 (1996), 1982–1992.

    PubMed  CAS  Google Scholar 

  57. Fisher, B., J. Dignam, S. Wiegand, N. Wolmark, D. L. Wickerham, and contributing investigators: Duration of tamoxifen (TAM) therapy for primary breast cancer: 5 versus 10 years (NSABP B-14). Proc. ASCO 15 (1996), Nr. 118.

    Google Scholar 

  58. Fisher, B., S. Anderson, C. K. Redmond, N. Wolmark, D. L. Wickerham, W. M. Cronin: Renalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of brest cancer. New Engl. J. Med. 333 (1995), 1456–1461.

    Article  PubMed  CAS  Google Scholar 

  59. Fitzgerald, M. G., D. J. MacDonald, M. Krainer, I. Hoover, E. O’Neil, H. Unsal, S. Silva-Arrieto, D. M. Finkelstein, P. Beer-Romero, C. Englert, D. C. Sgroi, B. L. Smith, J. W. Younger, J. E. Garber, R. B. Duda, K. A. Mayzel, K. J. Isselbacher, S. H. Friend, D. A. Haber: Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. New Engl. J. Med. 334 (1996), 143–149.

    Article  PubMed  CAS  Google Scholar 

  60. Foss, F. M., D. C. Ihde, I. R. Linnoila, A. B. Fischmann, G. P. Schechter, J. D. Cotelingam, S. M. Steinberg, B. C. Ghosh, J. L. Stocker, A. Bastian, J. C. Phares, E. A. Sausville: Phase II trial of fludarabine phosphate and interferon alpha-2a in advanced mycosis fungoides/Sézary syndrome. J. clin. Oncol. 12 (1994), 2051–2059.

    PubMed  CAS  Google Scholar 

  61. Fossella, F. V., J. S. Lee, D. M. Shin, M. Calayag, M. Huber, R. Perez-Soler, W. K. Murphy, S. Lippman, S. Benner, B. Glisson, M. Chasen, W. K. Hong, M. Raber: Phase II study of docetaxel for advaced or metastatic platinum-refractory non-small-cell lung cancer. J. clin. Oncol. 13 (1995), 645–651.

    PubMed  CAS  Google Scholar 

  62. Fraker, D. L., H. R. Alexander, M. Andrich, S. A. Rosenberg: Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-excalation study. J. clin. Oncol. 14 (1996), 479–489.

    PubMed  CAS  Google Scholar 

  63. French Cooperative Group on CLL, S. Johnson, A. G. Smith, H. Löffler, E. Ösby, G. Juliusson, B. Emmerich, P. J. Wyld, W. Hiddemann: Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorucicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet 347 (1996), 1432–1437.

    PubMed  CAS  Google Scholar 

  64. Fridrik, M. A., H. Hausmaninger, W. Linkesch, M. Stöger, H. Sill, M. Neubauer, H. L. Seewann, J. Klocker, R. Haidinger, L. Schiller, J. Pont, G. Raudachl, M. Falk, T. Radaszkiewicz: CEOP-IMVP-DEXA in the treatment of aggressive lymphomas an Austrian multicenter trial. J. clin. Oncol. 14 (1996), 227–232.

    PubMed  CAS  Google Scholar 

  65. Fujita, K., H. Ikarashi, K. Takakuwa, S. Kodama, A. Tokunaga, T. Takahashi, K. Tanaka: Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Clin. Cancer Res. 1 (1995), 501–507.

    PubMed  CAS  Google Scholar 

  66. Fyfe, G., R. I. Fisher, S. A. Rosenberg, M. Sznol, D. R. Parkinson, A. C. Louie: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. clin. Oncol. 13 (1995), 688–696.

    PubMed  CAS  Google Scholar 

  67. Gale, R. P., M. M. Horowitz, J. K. H. Rees, R. G. Gray, M. M. Oken, E. H. Estey, K. M. Kim, M.-J. Zhang, R. C. Ash, K. Atkinson, R. E. Champlin, K. A. Dicke, J. L. Gajewski, J. M. Goldman, W. Helbig, P. J. Henslee-Downey, W. Hinterberger, N. Jacobsen, A. Keating, J. P. Klein, A. M. Marmont, H. G. Prentice, J. Reiffers, A. A. Rimm, P. A. Rowlings, K. A. Sobocinsi: Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia 10 (1996), 13–19.

    PubMed  CAS  Google Scholar 

  68. Galligioni, E., M. Quaia, A. Merlo, A. Carbone, A. Spada, D. Favoro, M. Santarosa, C. Sacco, R. Talamini, the Gruppo Oncologico Clinico Cooperativo del Nord-Est: Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin. Five-year results of a prospective randomized study. Cancer (Philad.) 77 (1996), 2560–2566.

    Article  CAS  Google Scholar 

  69. Gelber, R. D., B. F. Cole, A. Goldhirsch, C. Rose, B. Fisher, C. K. Osborne, F. Boccardo, R. Greay, N. H. Gordon, N.-O. Bengtsson, P. Sevelda: Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet 347 (1996), 1066–1071.

    Article  PubMed  CAS  Google Scholar 

  70. Giovannucci, E., K. M. Egan, D. J. Hunter, M. J. Stampfer, G. A. Golditz, W. C. Willet, F. E. Speizer: Aspirin and the risk of colorectal cancer in women. New Engl. J. Med. 333 (1995), 609–614.

    Article  PubMed  CAS  Google Scholar 

  71. Gjertsen, M. K., A. Bakka, J. Breivik, I. Saeterdal, B. G. Solheim, O. Søreide, E. Thorsby, G. Gaudernack: Vaccination with mutant ras peptides an induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 346 (1995), 1399–1400.

    Article  PubMed  CAS  Google Scholar 

  72. Goldhirsch, A., W. C. Wood, H. J. Senn, J. H. Glick, R. D. Gleber: Meeting highlights: international consensus panel on the treatment of primary breast cancer. J. nat. Cancer Inst. 87 (1995), 1441–1445.

    Article  PubMed  CAS  Google Scholar 

  73. Gordon, L. I., J. Anderson, T. M. Habermann, J. N. Winter, J. Glick, R. J. Schilder, P. Cassileth: Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytoBOM. J. clin. Oncol. 14 (1996), 1275–1281.

    PubMed  CAS  Google Scholar 

  74. Graham, B. S., P. F. Wright: Candidate AIDS vaccines. New Engl. J. Med. 333 (1995), 1331–1339.

    Article  PubMed  CAS  Google Scholar 

  75. Grever, M., K. Kopecky, M. K. Foucar, D. Head, J. M. Bennet, R. E. Hutchison, W. E. N. Corbett, P. A. Cassileth, T. Habermann, H. Golomb, K. Rai, E. Eisenhauer, F. Appelbaum, B. D. Cheson: Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J. clin. Oncol. 13 (1995), 974–982.

    PubMed  CAS  Google Scholar 

  76. Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire: A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. New Engl. J. Med. 332 (1995), 1256–1261.

    Article  Google Scholar 

  77. Ham, S. J., H. J. Hoekstra, W. T. A. van der Graaf, W. A. Kamps, W. M. Molenaar, H. Schraffordt Koops: The value of high-dose methotrexate based neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone. J. clin. Oncol. 14 (1995), 490–496.

    Google Scholar 

  78. Hardingham, J. E., D. Kotasek, R. E. Sage, L. T. Gooley, J.-X. Mi, A. Dobrovic, J. E. Norman, A. E. Bolton, B. M. Dale: Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin’s lymphoma. J. clin. Oncol. 13 (1995), 1073–1079.

    PubMed  CAS  Google Scholar 

  79. Hartmann, F., C. Renner, W. Jung, C. Deisting, M. Juwanh, M. Pfreundschuh: Response of refractory Hodgkin’s disease to treatment with an anti-CD30/CD16 bispecific antibody: Results of a phase-I/II study. Proc. ASCO 15 (1996), Nr. 1384.

    Google Scholar 

  80. Harris, N. L., E. S. Jaffe, H. Stein, P. M. Banks, J. K. C. Chan, M. L. Cleary, G. Delsol, C. De Wolf-Peeters, B. Falini, K. C. Gatter, T. M. Grogan, P. G. Isaacson, D. M. Knowles, D. Y. Mason, H.-K. Müller-Hermelink, S. A. Pileri, M. A. Piris, E. Ralfkiaer, R. A. Warncke: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84 (1994), 1361–1392.

    PubMed  CAS  Google Scholar 

  81. Harrison, M., D. Tomlinson, S. Stewart: Liposomal-entrapped doxorubcin: an active agent in AIDS-related Kaposi’s sarcoma. J. clin. Oncol. 13 (1995), 914–920.

    PubMed  CAS  Google Scholar 

  82. Hatz, R. A., N. Lehn, S. Leyh, M. F. Kaps, E. Bayerdorffer, M. Stolte, F. W. Schildberg: Die Prävalenz der Helicobacter pylori Infektion beim Magenkarzinom. Chirurg 67 (1996), 403–408.

    PubMed  CAS  Google Scholar 

  83. Hayashi, N., I. Ito, A. Yanagisawa, Y. kato, S. Nakamori, S. Imaoka, H. Watanabe, M. Ogawa, Y. Nakamura: Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet 345 (1995), 1257–1259.

    Article  PubMed  CAS  Google Scholar 

  84. Heiss, M. M., R. Babic, H. Allgayer, K. U. Gruetzner, K. W. Jauch, U. Loehrs, F. W. Schildberg: Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J. clin. Oncol. 13 (1995), 2084–2093

    PubMed  CAS  Google Scholar 

  85. Heiss, M. M., H. Allgayer, K. U. Gruetzner, I. Funke, R. Babic, K. W. Jauch, F. W. Schildberg: Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nature Med. 1 (1995), 1035–1039

    Article  PubMed  CAS  Google Scholar 

  86. Heslin, M. J., J. Woodruff, M. F. Brennan: Prognostic significance of a positive microscopic margin in high-risk extremity soft tissue sarcoma: implications for management. J. clin. Oncol. 14 (1996), 373–478.

    Google Scholar 

  87. Hill, M., A. Norman, D. Cunningham, M. Findlay, V. Nicolson, A. Hill, A. Iveson, C. Evans, J. Joffe, M. Nicolson, T. Hickish: Royal Marsden Phase III Trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J. clin. Oncol. 13 (1995), 1297–1302.

    PubMed  CAS  Google Scholar 

  88. Hoelzer, D., W.-D. Ludwig, E. Thiel, W. Gaßmann, H. Löffler, C. Fonatsch, H. Rieder, G. Heil, B. Heinze, R. Arnold, D. Hossfeld, T. Büchner P. Koch, M. Freund, W. Hiddemann, G. Maschmeyer, A. Heyll, C. Aul, T. Fakak, R. Kuse, T. H. Ittel, M. Gramatzki, H. Diedrich, K. Kolbe, H.-G. Fuhr, K. Fischer, C. Schadeck-Gressel, A. Weiss, I. Stroscheer, B. Metzner, U. Fabry, N. Gökbuget, B. Völkers, D. Messerer, K. Überla: Improved outcome in adult B-cell acute lymphoblastic leukenia. Blood 87 (1996), 495–508.

    PubMed  CAS  Google Scholar 

  89. Honkoop, A. H., K. Hoekman, J. Wagstaff, E. Boven, C. J. van Groeningen, G. Giaccone, J. B. Vermorken, H. M. Pinedo: Dose-intensive chemotherapy with doxorubicin, cyclophosphamide and GM-CSF fails to improve survival of metastatic breast cancer patients. Ann. Oncol. 7 (1996), 35–39.

    PubMed  CAS  Google Scholar 

  90. Lotz, J.-P., T. André, R. Donsimoni, C. Firmin, C. Bouleuc, H. Bonnak, Z. Merad, A. Esteso, J. Gerota, V. Izrael: High dose chemotherapy with ifosfamide. carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poorprognosis germ cell tumors and metastatic trophoblastic disease in adults. Cancer (Philad.) 75 (1995): 874–885.

    Article  CAS  Google Scholar 

  91. Mamounas, E. P., H. Rockette, J. Jones, S. Wieand, D. L. Wickerham, B. Fisher, N. Wolmark: Comparative efficacy of adjuvant chemotherapie in patients with Duke’s B vs. Duke’s C colon cancer: results from four NSABP adjuvant studies. Proc. ASCO 15 (1996), Nr. 461.

    Google Scholar 

  92. MacManus, M. P., R. T. Hoppe: Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J. clin. Oncol. 14 (1996), 1282–1283.

    CAS  Google Scholar 

  93. Marino, P., A. Preatoni, A. Cantoni: Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. Cancer (Philad.) 76 (1995), 593–601.

    Article  CAS  Google Scholar 

  94. Marsh, R., N.-M. Chu, J.-N. Vauthey, W. M. Mendenhall, G. Y. Lauwers, C. Bewsher, E. M. Copeland: Preoperative treatment of patients with locally advanced unresectable rectal adenocarcinoma utilizing continuous chronobiologically shaped 5-fluoroucil infusion and radiation therapy. Cancer (Philad.) 78 (1996), 217–225.

    Article  CAS  Google Scholar 

  95. Martelli, M., M. Vignetti, P. L. Zinzani, F. Gherlinzoni, G. Meloni, M. Fiacchini, V. DeSanctis, G. Papa, M. F. Martelli, F. Calabresi, S. Tura, F. Mandelli: High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin’s lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study. J. clin. Oncol. 14 (1996), 534–542.

    PubMed  CAS  Google Scholar 

  96. Mauch, P. M., G. P. Canellos, L. N. Shulman, B. Silver, N. J. Tarbell, S. Come, M. S. Rabin, C. N. Coleman: Mantle irradiation alone for selected patients with laparotomy-staged IA to IIA Hodgkin’s disease: preliminary results of a prospective trial. J. clin. Oncol. 13 (1995), 947–952.

    PubMed  CAS  Google Scholar 

  97. Mayer, R. J., R. B. Davis, C. A. Schiffer, D. T. Berg, B. L. Powell, P. Schulman, G. A. Omura, J. O. Moore, O. R. McIntyre, E. Frei III, for the Cancer and Leukemia Group B: Intensive postremission chemotherapy in adults with acute myeloid leukemia. New Engl. J. Med. 331 (1994), 896–903.

    Article  PubMed  CAS  Google Scholar 

  98. Mazzaferro, V., E. Regalia, R. Doci, S. Andreola, A. Pulvirenti, F. Bozzetti, F. Montalto, M. Ammatuna, A. Morabito, L. Gennari: Liver transplatation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New Engl J. Med. 334 (1996), 693–699.

    Article  PubMed  CAS  Google Scholar 

  99. McGuire, W. P., J. A. Blessing, D. Moore, S. S. Lentz, G. Photopulos: Paclitaxel has moderate activity in squamous cervix cancer: a gynecologic oncology group study. J. clin. Oncol. 14 (1996), 792–795.

    PubMed  CAS  Google Scholar 

  100. McGuire, W. P., W. J. Hoskins, M. F. Brady, H. D. Homesley, W. T. Creasman, M. L. Berman, H. Ball, J. S. Berek, J. Woodward: Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a gynecologic oncology groups study. J. clin. Oncol. 13 (1995), 1589–1599.

    PubMed  CAS  Google Scholar 

  101. McGuire, W. P., W. J. Hoskins, M. F. Brady, P. R. Kucera, E. E. Partridge, K. Y. Look, D. L. Clarke-Pearson, M. Davison: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Engl. J. Med. 334 (1996), 1–6.

    Article  PubMed  CAS  Google Scholar 

  102. McLaughlin, P., F. B. Hagemeister, J. E. Romaguera, A. H. Sarris, O. Pate, A. Younes, F. Swan, M. Keating, F. Cabanillas: Fludarabine, mitoxantrone, dexamethasone: an effective new regimen for indolent lymphoma. J. clin. Oncol. 14 (1996), 1262–1268.

    PubMed  CAS  Google Scholar 

  103. Mercieca, J., E. Matutes, C. Dearden, K. MacLennan, D. Catovsky: The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J. clin. Oncol. 12 (1994), 2588–2593.

    PubMed  CAS  Google Scholar 

  104. Merlano, M., M. Benasso, R. Corvò, R. Rosso, V. Vitale, F. Blengio, G. Numico, G. Margarino, L. Bonelli, L. Santi: Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J. nat. Cancer Inst. 88 (1996), 583–589.

    Article  PubMed  CAS  Google Scholar 

  105. Merrouche, Y., S. Negrier, C. Bain, V. Combaret, A. Mercatello, B. Coronel, J.-F. Moskovtchenko, P. Tolstoshev, R. Moen, T. Philip, M. C. Favrot: Clinical application of retroviral gene transfer in oncology: results of a french study with tumor-infiltrating lymphocytes transduced with the gene of resistance of neomycin. J. clin. Oncol. 13 (1995), 410–418.

    PubMed  CAS  Google Scholar 

  106. Meta-Analysis Group in Cancer: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J. nat. Cancer Inst. 88 (1996), 252–258.

    Article  Google Scholar 

  107. Mettlin, C. P. J. Littrup, R. A. Kane, G. P. Murphy, F. Lee, A. Chesley, R. Badalament, F. K. Mosstofi for the Investigators of the American Cancer Society National Prostate Cancer Detection Project: Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Cancer (Philad.) 74 (1994), 1615–1620.

    Article  CAS  Google Scholar 

  108. Miller, A. A., J. E. Herndon II, D. R. Hollis, J. Ellerton, A. Langleben, F. Richards II, M. R. Green: Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the cancer and leukemia group B. J. clin. Oncol. 13 (1995), 1871–1879.

    PubMed  CAS  Google Scholar 

  109. Miller, T. P., S. Dahlberg, J. R. Cassady, C. Spier, T. M. Grogan, S. Carlin, E. Chase, R. I. Fisher: Three cycles of chop (3) plus radiotherapy (rt) is superior to eight cycles of chop (8) alone for localized intermediate and high grade non-Hodgkin’s lymphoma (NHL): a Southwest Oncology Group Study. Proc. ASCO 15 (1996), Nr. 1257.

    Google Scholar 

  110. Milpied, N., A. K. Fielding, R. M. Pearce, P. Ernst, A. H. Goldstone for the European Group for Blood and Marrow Transplatation: Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin’s disease. J. clin. Oncol. 14 (1996), 1291–1296.

    PubMed  CAS  Google Scholar 

  111. Minasian, L. M., T. J. Yao, T. A. Steffens, D. A. Scheinberg, L. Williams, E. Riedel, A. N. Houghton, P. B. Chapman: A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma. Cancer (Philad.) 75 (1995), 2251–2257.

    Article  CAS  Google Scholar 

  112. Minsky, D., D. Neuberg, D. P. Kelsen, T. M. Pisansky, R. Ginsberg, A. Benson III: Neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose-radiation for squamous cell carcinoma of the esophagus: a preliminary analysis of the phase II intergroup trial 0122. J. clin. Oncol. 14 (1996), 149–155.

    PubMed  CAS  Google Scholar 

  113. Misset, J.-L., M. di Palma, M. Delgado, R. Plagne, P. Chollet, P. Fumoleau, B. Le Mevel, D. Belpomme, J. Guerrin, P. Fargeot, R. Metz, M. Ithzaki, C. Hill, G. Mathé for the Groupe Oncofance: Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. J. clin. Oncol. 14 (1996), 1136–1145.

    PubMed  CAS  Google Scholar 

  114. Moertel, C. G., T. R. Fleming, J. S. Macdonald, D. G. Haller, J. A. Laurie, C. M. Tangen, J. S. Ungerleider, W. A. Emerson, D. C. Tormey, J. H. Glick, M. H. Veeder, J. A. Mailliard: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann. intern. Med. 122 (1995), 321–326.

    PubMed  CAS  Google Scholar 

  115. Moertel, C. G., T. R. Fleming, J. S. Macdonald, D. G. Haller, J. A. Laurie, C. M. Tangen, J. S. Ungerleider, W. A. Emerson, D. C. Tormey, J. H. Glick, M. H. Veeder, J. A. Maillard for the North Central Cancer Treatment Group, Southwest Oncology Group, and Eastern Cooperative Oncology Group: Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’B2 colon cancer. J. clin. Oncol. 13 (1995), 2936–2943.

    PubMed  CAS  Google Scholar 

  116. Mohinuddin, M., E. Chen, N. Ahmad: Combined liver radiation and chemotherapy for palliation of hepatic metastases from colorectal cancer. J. clin. Oncol. 14 (1996), 722–728.

    Google Scholar 

  117. Moore, S. P., Y. Chang: Detection of herpesvirus-like DNA sequences in Kaposi’s sarcoma in patients with and those without HIV infektion. New Engl. J. Med. 332 (1995), 1181–1185.

    Article  PubMed  CAS  Google Scholar 

  118. Morel, P., J. P. Laporte, M. P. Noel, M. Lopez, L. Douay, L. Fouillard, L. Detourmignies, B. Dupriez, S. Lesage, F. Isnard, M. Grande, J. P. Jouet, A. Najman, F. Bauters, N. C. Gorin: Autologous bone marrow transplantation as consolidation therapy may prolong remission in newly diagnosed high-risk follicular lymphoma: a pilot study of 34 cases. Leukemia 9 (1995), 576–582.

    PubMed  CAS  Google Scholar 

  119. Motzer, R. J., D. F. Bajorin, L. H. Schwartz, H. S. Hutter, G. J. Bosl, H. I. Scher, P. Lyn, P. Fischer: Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J. clin. Oncol. 12 (1994), 2277–2283.

    PubMed  CAS  Google Scholar 

  120. Motzer, R. J., L. Schwartz, T. M. Law, B. A. Murphy, A. D. Hoffman, A. P. Albino, V. Vlamis, D. M. Nanus: Interferon alpha-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J. clin. Oncol. 13 (1995), 1950–1957.

    PubMed  CAS  Google Scholar 

  121. Motzer, R. J., M. Mazumdar, G. J. Bosl, D. F. Bajorin, A. Amsterdam, V. Vlamis: High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J. clin. Oncol. 14 (1996), 1098–1105.

    PubMed  CAS  Google Scholar 

  122. Motzer, R., J. Sheinfeld, M. Mazumdar, D. F. Bajorin, G. J. Bosl, H. Herr, P. Lyn, V. Vlamis: Etoposide and cisplatin adjuvant therapy for pateints with pathologic stage II germ cell tumors. J. clin. Oncol. 13 (1995), 2700–2704.

    PubMed  CAS  Google Scholar 

  123. Nordic Myeloma Study Group: Interferon-α2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. a randomized, controlled trial. Ann. intern. Med. 124 (1996), 212–222.

    Google Scholar 

  124. Nordlinger, B., M. Guiguet, J.-C. Vaillant, P. Balldur, K. Boudjema, P. Bachallier, D. Jaeck, Association Francaise de Chirurgie: Surgical resection of colorectal carcinoma metastases to the liver. Cancer (Philad.) 77 (1996), 1254–1262.

    Article  CAS  Google Scholar 

  125. O’Conell, M. J., J. A. Martenson, H. S. Wieand, J. E. Krook, J. S. MacDonald, D. G. Haller, R. J. Mayer, L. L. Gunderson, T. A. Rich: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curativ surgery. New Engl. J. Med. 331 (1994), 502–507.

    Article  Google Scholar 

  126. Ockert D., V. Schirrmacher, N. Beck, E. Stoelben, T. Ahlert, J. Flechtenmacher, E. Hagmüller, R. Buchcik, M. Nagel, H.-D. Saeger: Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin. Cancer Res. 2 (1996), 21–28.

    PubMed  CAS  Google Scholar 

  127. Okada, S., T. Takayama, H. Ishii, H. Nose, H. Nakasuka, H. Nakayama, H. Nagahama, T. Okusaka, M. Yoshimori, K. Shimada, J. Yamamoto, T. Kosuge, S. Yamasaki, T. Sato: A comparative study between surgical resection and percutaneous ethanol injection for small hepatocellular carcinoma. Proc. ASCO 15 (1996), Nr. 439.

    Google Scholar 

  128. Omoto, E., S. Deguchi, S. Takaba, K. Kojima, T. Yano, Y. Katayama, K. Sunami, M. Takeuchi, F. Kimura, M. Harada, I. Kimura: Low-dose melphalane for treatment of high-risk myelodysplastic syndromes. Leukemia 10 (1996), 609–614.

    PubMed  CAS  Google Scholar 

  129. Overgaard, J., D. G. Gonzalez, M. C. C. M. Hulshof, G. Arcangeli, O. Dahl, O. Mella, S. M. Bentzen, for European Society for Hyperthermic Oncology: Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. Lancet 345 (1995), 540–543.

    Article  PubMed  CAS  Google Scholar 

  130. Pantel, K., J. Izbicki, B. Passlick, M. Angstwurm, K. Häussinger, O. Thetter, G. Riethmüller: Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 347 (1996), 649–653.

    Article  PubMed  CAS  Google Scholar 

  131. Patrone, F., A. Ballestrero, F. Ferrando, F. Brema, L. Maraglio, M. Valbonesi, P. Basta, R. Ghio, M. Gobbi, M. Sessarego: Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer. J. clin. Oncol. 13 (1995), 840–846.

    PubMed  CAS  Google Scholar 

  132. Pettengell, R., J. A. Radford, G. R. Morgenstern, J. H. Scarffe, M. Harris, P. J. Woll, D. P. Deakin, D. Ryder, P. M. Wilkinson, D. Crowther: Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin’s lymphoma. J. clin. Oncol. 14 (1996), 586–592.

    PubMed  CAS  Google Scholar 

  133. Pfreundschuh, M.: Update Onkologie ’94. Med. Klin 90 (1995), 144–159.

    CAS  Google Scholar 

  134. Philip, T., C. Guglielmi, A. Hagenbeek, R. Somers, H. van der Lelie, D. Bron, P. Sonneveld, C. Gisselbrecht, J.-Y. Cahn, J.-L. Harousseau, B. Coiffier, P. Biron, F. Mandelli, F. Chauvin: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. New Engl. J. Med. 333 (1995), 1540–1545.

    Article  PubMed  CAS  Google Scholar 

  135. Pisters, P. W. T., L. B. Harrson, D. H. Y. Leung, J. M. Woodruff, E. S. Casper, M. F. Brennan: Longterm results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J. clin. Oncol. 14 (1996), 859–868.

    PubMed  CAS  Google Scholar 

  136. Pont, J., W. Albrecht, G. Postner, F. Sellner, K. Angel, W. Höltl: Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous resticular germ cell cancer: long-term results of a prospective trial. J. clin. Oncol. 14 (1996), 441–448.

    PubMed  CAS  Google Scholar 

  137. Powles, T. J., A. Makris, S. E. Ashley, M. E. R. O’Brien, V. A. Tidy, S. Casey, A. G. Nash, N. Sacks, D. Cosgrove, D. Mac Vicar, I. Fernando, H. T. Ford: Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J. clin. Oncol. 13 (1995), 547–552.

    PubMed  CAS  Google Scholar 

  138. Press, O. W., J. F. Eary, F. R. Appelbaum, P. J. Martin, W. B. Nelp, S. Glenn, D. R. Fisher, B. Porter, D. C. Matthews, T. Gooley, I. D. Bernstein: Phase II trial of131/-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346 (1995), 336–340.

    Article  PubMed  CAS  Google Scholar 

  139. Prostata Cancer Trialists’ Collaborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 346 (1995), 265–269.

    Google Scholar 

  140. Puc, H. S., R. Heelan, M. Mazumdar, H. Herr, J. Scheinfeld, V. Vlamis, D. F. Bajorin, G. J. Bosl, P. Mencel, R. J. Motzer: Management of residual mass in avanced seminoma: results and recommendations from the memorial sloan-kettering cancer center. J. clin. Oncol. 14 (1996), 454–460.

    PubMed  CAS  Google Scholar 

  141. Pyrhönen, S., T. Kuitunen, P. Nyandoto, M. Kouri: Randomised comparison of fluorouracil, epidoxorubicin and methotrexat (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Brit. J. Cancer 71 (1995), 587–591.

    PubMed  Google Scholar 

  142. Radford, J. A., D. Crowther, A. Z. S. Rohatiner, W. D. J. Ryder, R. K. Gupta, A. Oza, D. P. Deakin, S. Arnott, P. M. Wilkinson, R. D. James, R. J. Johnson, R. A. Lister: Results of a randomized trial comparing mvpp chemotherapy with a hybrid regimen, ChIVPP/EVA, in the initial treatment of Hodgkin’s disease. J. clin. Oncol. 13 (1995), 2379–2385.

    PubMed  CAS  Google Scholar 

  143. Radich, J. P., g. Gehly, T. Gooley, E. Bryant, R. A. Clift, S. Collins, S. Edmands, J. Kirk, A. Lee, P. Kessler, G. Schoch, E. D. Buckner, K. M. Sullivan, F. R. Appelbaum, E. D. Thomas: Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 85 (1995), 2632–2638.

    PubMed  CAS  Google Scholar 

  144. Ratto, G. B., P. Zino, S. Mirabelli, P. Minuti, R. Aquilina, G. Fantino, E. Spessa, M. Ponte, P. Bruzzi, G. Melioli: A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. Cancer (Philad.) 78 (1996), 244–51.

    Article  CAS  Google Scholar 

  145. Recht, A., S. E. Come, C. Henderson, R. S. Gelman, B. Silver, D. F. Hayes, L. N. Shulman, J. R. Harris: The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. New Engl. J. Med. 334 (1996), 1356–1361.

    Article  PubMed  CAS  Google Scholar 

  146. Reckzeh, B., H. Merte, K.-H. Pflüger, R. Pfab, M. Wolf, K. Havemann: Severe lymphocytopenia and interstitial pneumonia in patients treated with pacliataxel and simultaneous radiotherapy for non-small-cell lung cancer. J. clin. Oncol. 14 (1996), 1071–1076.

    PubMed  CAS  Google Scholar 

  147. Rosen, P. J., E. F. Mendoza, E. M. Landaw, B. Mondino, M. C. Graves, J. H. McBride, P. Turcillo, J. deKernion, A. Belldegrun: Suramin in hormone-refractory metastatic protate cancer: a drug with limited efficacy. J. clin. Oncol. 14 (1996), 1626–1636.

    PubMed  CAS  Google Scholar 

  148. Roth, B. J., R. Dreicer, L. H. Einhorn, D. Neuberg, D. H. Johnson, J. L. Smith, G. R. Hudes, S. M. Schultz, P. J. Loehrer: Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urotheli um: a phase II trial of the Eastern Cooperative Oncology Group. J. clin. Oncol. 12 (1994), 2264–2270.

    PubMed  CAS  Google Scholar 

  149. Rothenberg, M. L., M. J. Moore, M. C. Cripps, J. S. Andersen, R. K. Portenoy, H. A. Burris III, M. R. Green, P. G. Tarasoff, T. D. Brown, E. S. Casper, A. M. Storniolo, D. D. Von Hoff: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann. Oncol. 7 (1996), 347–353.

    PubMed  CAS  Google Scholar 

  150. Rothenberg, M. L., J. R. Eckardt, J. G. Kuhn, H. A. Burris III, J. Nelson, S. G. Hilsenbeck, G. I. Rodriguez, A. M. Thurman, L. S. Smith, S. G. Eckhardt, G. R. Weiss, G. L. Elfring, D. A. Rinaldi, L. J. Schaaf, D. D. Von Hoff: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J. clin. Oncol. 14 (1996), 1128–1135.

    PubMed  CAS  Google Scholar 

  151. Rusthoven, J. J., I. C. Quirt, N. A. Iscoe, P. B. McCulloch, K. W. Janes, R. C. Lohmann, Jensen, S. Burdett-Radous, A. J. Bodurtha, H. K. B. Silver, S. Verma, G. R. Armitage, B. Zee, K. Bennett for the National Cancer Institute of Canada clinical Trials Group: Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J. clin. Oncol. 14 (1996), 2083–2090.

    PubMed  CAS  Google Scholar 

  152. Rustin, G. J. S., A. E. Nelstrop, P. McClean, M. F. Brady, W. P. McGuire, W. J. Hoskins, H. Mitchell, H. E. Lambert: Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J. clin. Oncol. 14 (1996), 1545–1551.

    PubMed  CAS  Google Scholar 

  153. Sagaster, P., M. Micksche, J. Flamm, H. Ludwig: Randomised study using IFN-α versus IFN-α plus coumarin and cimetidine for treatment of advenced renal cell cancer. Ann. Oncol. 6 (1995), 999–1003.

    PubMed  CAS  Google Scholar 

  154. Santoro, A., T. Tursz, H. Mouridsen, J. Verweij, W. Steward, R. Somers, J. Buesa, P. Casali, D. Spooner, E. Rankin, A. Kirkpatrick, M. Van Glabbeke, A. van Oosterom: Doxorubicin versus CYVADIC versus doxorucicin plus ifosfamide in first-line-treatment of advanced soft tissue sarcomas: a randomized study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. J. clin. Oncol. 13 (1995), 1537–1545.

    PubMed  CAS  Google Scholar 

  155. Sause, W. T., C. Scott, S. Taylor, D. Johnson, R. Livingston, R. Komaki, B. Emami, W. J. Curran, R. W. Byhardt, A. T. Turrisi, A. R. Dar, J. D. Cox: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J. nat. Cancer Inst. 87 (1995) 198–205.

    Article  PubMed  CAS  Google Scholar 

  156. Saville, M. W., J. Lietzau, J. M. Pluda, I. Feuerstein, J. Odom, W. H. Wilson, R. W. Humphrey, E. Feigal, S. M. Steinberg, S. Broder, R. Yarchoan: Treatment of HIV-associated Kaposi’s sarcoma with paclitaxel. Lancet 346 (1995), 26–28.

    Article  PubMed  CAS  Google Scholar 

  157. Schlegelberger, B., T. Zwingers, K. Hohenadel, D. Henne-Bruns, N. Schmitz, T. Haferlach, C. Tirier, H. Bartels, R. Sonnen, R. Kuse, W. Grote: Significance of cytogenetic findings for the clinical outcome in patients with t-cell lymphoma of angioimmunoblastic lymphadenopathy type. J. clin. Oncol. 14 (1996), 593–599.

    PubMed  CAS  Google Scholar 

  158. Schmitz, N., D. C. Linch, P. Dreger, A. H. Goldstone, M. A. Boogaerts, A. Ferrant, H. M. S. Demuynck, H. Link, A. Zander, A. Barge, K. Borkett: Randomised trial of filgrastim-mobilised peripheral blood progenitor transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347 (1996), 353–357.

    Article  PubMed  CAS  Google Scholar 

  159. Sebban, C., for the French Group of Therapy of Adult Acute Lymphoblastic Leukemia: Allogeneic bone marrow transplantation in adult acute leukemia in first complete remission: a comparative study. J. clin. Oncol. 12 (1994), 2580–2587.

    PubMed  CAS  Google Scholar 

  160. Seidman, A. D., B. S. Reichman, J. P. A. Crown, T.-J. Yao, V. Currie, T. B. Hakes, C. A. Hudis, T. A. Gilewski, J. Baselga, P. Forsythe, J. Lepore, L. Marks, K. Fain, M. Souhrada, N. Onetto, S. Arbuck, L. Norton: Pachtaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J. clin. Oncol. 13 (1995), 1152–1159.

    PubMed  CAS  Google Scholar 

  161. Seitz, J. F., D. Cunningham, U. Rath, I. N. Olver, E. van Cutsem, D. Kerr, C. Svensson, G. Perez Manga, P. Harper, J. Zalcberg, K. Lowery, M. Azab: Final results and survival data of a large randomised trial of ‘Tomudex’ in advanced colorectal cancer confirm comparable efficacy to 5-fluorouracil plus leucovorin. Proc. ASCO 15 (1996), Nr. 446.

  162. Sharp J. G., A. Kessinger, S. Mann, D. A. Crouse, J. O. Armitage, P. Bierman, D. D. Weisenburger: Outcome of high-dose therapy and autologous transplantation in non-Hodgkin’s lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J. clin. Oncol. 143 (1996), 214–219.

    Google Scholar 

  163. Shaw, E. G. J. Q. Su, R. T. Eagan, J. R. Jett, A. W. Maksymiuk, F. A. Deigert: Prophylactic cranial irradiation in complete responders with small-cell lung cancer: analysis of the Mayo Clinic and North Central Cancer Treatment Group Data Bases. J. clin. Oncol. 12 (1994), 2327–2332.

    PubMed  CAS  Google Scholar 

  164. Shipp, M. A., D. Neuberg, M. Janicek, G. P. Canellos, L. N. Shulman: High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin’s lymphoma: a dose-finding pilot study. J. clin. Oncol. 13 (1995), 2916–2923.

    PubMed  CAS  Google Scholar 

  165. Silverstein, M. J., D. N. Poller, J. R. Waisman, W. J. Colburn, A. Barth, E. D. Gierson, B. Lewinsky, P. Gamagami, D. J. Slamon: Prognostic classification of breast ductal carcinoma-in-situ. Lancet 345 (1995), 1154–1157.

    Article  PubMed  CAS  Google Scholar 

  166. Small, E. J., S. Srinivas, B. Egan, A. McMillan, T. P. Rearden: Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant protate cancer. J. clin. Oncol. 14 (1996), 1617–1625.

    PubMed  CAS  Google Scholar 

  167. Solin, L. J., J. Kurtz, A. Fouquet, R. Amalric, A. Recht, B. A. Bornstein, R. Kuske, M. Taylor, W. Barrett, B. Fowble, B. Haffty, D. J. Schultz, I.-T. Yeh, B. McCormick, M. McNeese: Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J. clin. Oncol. 14 (1996), 754–763.

    PubMed  CAS  Google Scholar 

  168. Sonneveld, P., M. de Ridder, H. van der Lelie, K. Nieuwenhuis, H. Schouten, A. Mulder, I. van Reijswoud, W. Hop, B. Löwenberg: Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin’s lymphoma using CHOP versus CNOP chemotherapy. J. clin. Oncol. 13 (1995), 2530–2539.

    PubMed  CAS  Google Scholar 

  169. Stahl, M., H. Wilke, U. Fink, M. Stuschke, M. K. Walz, J. R. Siewert, M. Molls, W. Fett, H.-B. Makoski, N. Breuer, U. Schmidt, W. Niebel, H. Sack, F. W. Eigler, S. Seeber: Combined preoperative chemotherapy and radiotherapy in patients with locally advanced eosphageoal cancer: interim analysis of a phase II trial. J. clin. Oncol. 14 (1996), 829–837.

    PubMed  CAS  Google Scholar 

  170. Steyerberg, E. W., H. J. Fossá, D. Th. Sleijfer, G. C. Toner, H. S. Koops, P. F. A. Mulders, J. E. Messemer, K. Ney, J. P. Donohue, D. Bajorin, G. Stoter, G. J. Bosl, J. D. F. Habbema: Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J. clin. Oncol. 13 (1995), 1177–1187.

    PubMed  CAS  Google Scholar 

  171. Stone, R. M., D. T. Berg, S. L. George, R. K. Dodge, P. A. Paciucci, P. Schulman, E. J. Lee, J. O. Moore, B. L. Powell, C. A. Schiffer, for the Cancer and Leukemia Group B: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. New Engl. J. Med. 332 (1995), 1671–1677.

    Article  PubMed  CAS  Google Scholar 

  172. Sutton, L., C. Chastang, P. Ribaud, J.-P. Jouet, M. Kuentz, M. Attal, X. Troussard, N. Milpied, F. Witz, P. Oriol, J.-Y. Cahn, M. Michaellet, E. Gluckman, N. Ifrah, J.-L. Pico, E. Vilmer, V. Leblond for the Société Française de Greffe de Moelle: Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long term study of 71 patients. Blood 88 (1996), 358–365.

    PubMed  CAS  Google Scholar 

  173. Swedish Breast Cancer Coooperative Group: Randomized trial of 2 versus 5 years of adjuvant tomoxifen in postmenopausal early-stage breast cancer. Proc. ASCO 15 (1996), Nr. 126.

    Google Scholar 

  174. Tallmann, M. S., R. Greay, J. M. Bennet, D. Variakojis, N. Robert, W. C. Wood, J. M. Rowe, P. H. Wiernik: Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group Experience. J. clin. Oncol. 13 (1995), 1557–1563.

    Google Scholar 

  175. Tattersall, M. H. N., V. Vootiprux, A. Cherisilpa, F. Wong, T. Azhar, H. P. Lee, S. B. Kang, A. Manalo, M.-S. Yen, N. Kampono, F. Aziz for the Cervical Cancer Study Group of the Asian Oceanian Clinical Oncology Association: Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advenced cervical cancer. J. clin. Oncol. 13 (1995), 444–451.

    PubMed  CAS  Google Scholar 

  176. Teodorovic, I., S. Pittaluga, J. C. Kluin-Nelemans, J. H. Meerwaldt, A. Hagenbeek, M. van Glabbeke, R. Somers, L. Bijnens, E. M. Nordijk, C. De Wolf Peeters for the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group: Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin’s lymphoma subtypes. J. clin. Oncol. 13 (1995), 2819–2826.

    PubMed  CAS  Google Scholar 

  177. Tester, W., R. Caplan, J. Heaney, P. Venner, R. Whittington, R. Byhardt, L. True, W. Shipley: Neo-adjuvant combined modality program with selective organ preservation for invasive bladder cander: results of radiation therapy oncology group phase II trial 8802. J. clin. Oncol. 14 (1996), 119–126.

    PubMed  CAS  Google Scholar 

  178. Thorlacius, S., L. Tryggvadottir, G. H. Olafsdottir, J. G. Janasson, H. M. Ogmundsdottir, H. Tulinius, J. E. Eyfjord: Linkage to BRCA2 region in hereditary male breast cancer. Lancet 346 (1995), 544–545.

    Article  PubMed  CAS  Google Scholar 

  179. Thigpen, J. T., P. A. Blessing, P. J. DiSaia: A randomized comparison of doxorbicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a gynecologic oncology group study. J. clin. Oncol. 12 (1995), 1408–1414.

    Google Scholar 

  180. Unterhalt, M., R. Herrmann, M. Tiemann, R. Parwaresch, H. Stein, L. Trümper, M. Nahler, M. Reuss-Borst, C. Tirier, A. Neubauer, M. Freund, E.-D. Kreser, H. Dietzfelbinger, H. Bodenstein, A. Engert, R. Stauder, H. Eimermacker, K. Landys, W. Hiddemann for the German Low-Grade Lymphoma Study Group: Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin’s lymphoma. Leukemia 10 (1996), 836–843.

    PubMed  CAS  Google Scholar 

  181. Valone, F. H., P. A. Kaufmann, P. M. Guyre, L. D. Lewis, V. Memoli, Y. Deo, R. Graziano, J. L. Fisher, L. Meyer, M. Mrozek-Orlowski, K. Wardwell, V. Guyre, T. L. Marley, C. Arvizu, M. W. Fanger: Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J. clin. Oncol. 13 (1995), 2281–2292.

    PubMed  CAS  Google Scholar 

  182. Van Besien, K. W., I. F. Khouri, S. A. Giralt, P. McCarthy, R. Mehra, B. S. Andersson, D. Przepiorka, J. L. Gajewski, N. Bellare, R. Nath, J. E. Romaguera, P. McLaughlin, M. Korblin, A. Deisseroth, F. F. Cabanillas, R. E. Champlin. Allogeneic bone marrow transplantation for refractory and recarrent low-grade lymphoma: the case for aggressive management. J. clin. Oncol. 13 (1995), 1096–1102.

    PubMed  Google Scholar 

  183. Van der Burg, M. E. L., M. van Lent, M. Buyse, A. Kobierska, N. Colombo, G. Favalli, A. J. Lacave, M. Nardi, J. Renard, S. Pecorelli for the Gynecological Cancer Cooperative Group of the European Organzation for Research and Treatment of Cancer: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. New Engl. J. Med. 332 (1996), 629–634.

    Article  Google Scholar 

  184. Van Geel, A. N., U. Pastorino, K. W. Jauch, I. R. Judson, F. van Coevorden, J. M. Buesa, O. S. Nielsen, A. Boudinet, T. Tursz, P. I. M. Schmitz: Surgical treatment of lung metastases. The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group Study of 255 patients. Cancer (Philad.) 77 (1996), 675–682.

    Article  Google Scholar 

  185. Verdonck, L. F., W. L. J. van Putten, A. Hagenbeek, H. C. Schouten, P. Sonneveld, G. W. van Imhoff, H. C. Kluin-Nelemans, J. M. M. Raemaekers, R. H. J. van Oers, H. L. Haak, R. Schots, A. W. Dekker, G. C. de Gast, B. Löwenberg: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin’s lymphoma. New Engl. J. Med. 332 (1995), 1045–1051.

    Article  PubMed  CAS  Google Scholar 

  186. Vokes, E. E., R. K. Rosenberg, M. Jahanzeb, J. B. Craig, R. J. Gralla, C. P. Belani, S. E. Jones, J. W. Bigley, J. A. Hohneker: Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer. J. clin. Oncol. 13 (1995), 637–644.

    PubMed  CAS  Google Scholar 

  187. Wada, H., S. Hitomi, T. Teramatsu, and the West Japan Study Group for Lung Cancer Surgery: Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. J. clin. Oncol. 14 (1996), 1048–1054.

    PubMed  CAS  Google Scholar 

  188. Wadler, S., H. Haynes, J. J. Beitler, X. Hu, S. Fell, M. Camacho, B. Levine, P. H. Wiermik: Phase II clinical trial with 5-fluorouracil, recombinant interferon-α-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus. Cancer (Philad.) 78 (1996), 30–34.

    Article  CAS  Google Scholar 

  189. Wagener, D. J. Th., H. E. R. Verdonk, L. Y. Dirix, G. Catimel, P. Segenthaler, M. Buitenhuis, A. Mathieu-Boué, J. Verweij: Phase II trial of CPT-11 in patients with advanced pancreatic cancer. An EORTC Early Clincal Trials Group Study. Ann. Oncol. 6 (1995), 129–132.

    PubMed  CAS  Google Scholar 

  190. Walsh, T. N., N. Noonan, D. Hollywood, A. Kelly, N. Kelling, T. P. J. Hennessy: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. New Engl. J. Med. 335 (1996), 462–467.

    Article  PubMed  CAS  Google Scholar 

  191. Warde, P., M. K. Gospodarowicz, T. Panzarella, C. N. Catton, J. F. G. Sturgeon, M. Moore, P. Goodman, M. A. S. Jewett: Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J. clin. Oncol. 13 (1995), 2255–2262.

    PubMed  CAS  Google Scholar 

  192. Warwick, J., S. Kehoe, H. Earl, D. Luesley, C. Redman, K. K. Chan: Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials. Brit. J. Cancer 72 (1995), 1513–1517.

    PubMed  CAS  Google Scholar 

  193. Webb, A., D. Cunningham, J. H. Scarffe, P. Harper, A. Norman, J. K. Joffee, M. Hughes, J. Mansi, M. Findlay, A. Hill, M. Nicolson, T. Hickish, M. O’Brien, T. Iveson, M. Watson, C. Underhillf, A. Wardley, M. Meehan: A randomized trial comparing ECF with FAMTX in advanced oesophago-gastric cancer. Proc. ASCO 15 (1996), Nr. 1462.

  194. Weber, B. L., C. Vogel, S. Jones, H. Harvey, L. Hutchins, J. Bigley, J. Hohneker: Intravenous venorelbine as first-line and second-line therapy in advenced breast cancer. J. clin. Oncol. 13 (1995), 2722–2730.

    PubMed  CAS  Google Scholar 

  195. Wilson, H. W., S. E. Bates, A. Fojo, G. Bryant, Z. Zhan, J. Regis, R. E. Wittes, E. S. Jaffe, S. M. Steinberg, J. Herdt, B. A. Chabner: Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J. clin. Oncol. 13 (1995), 1995–2004.

    PubMed  CAS  Google Scholar 

  196. Wollmark, N., H. Rockette, E. P. Mamounas, J. Jones, N. Petrelli, J. Atkins, N. Dimitroy, R. Pugh, D. L. Wickerham, S. Wieand, B. Fisher: The relative efficacy of 5-FU+leucovorin, 5-FU+levamisole, and 5-FU+leucovorin+levamisole in patients with Dukes’ B and C carcinoma of the colon: first report of NSABP C-04. Proc. ASCO 15 (1996), Nr. 460.

  197. Wozniak, A. J., J. J. Crowley, S. P. Balcerzak, G. R. Weiss, L. R. Laufman, L. H. Baker, R. I. Fisher, S. I. Bearman, S. A. Taylor, R. B. Livingston: Randomized phase III trial of cisplatin (CDDP) vs. CDDP plus navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC): report of a Southwest Oncology Group Study (SWOG-9308). Proc. ASCO 15 (1996), Nr. 1110.

  198. Zalcberg, J. R., D. Cunningham, E. Van Cutsem, E. Francois, J. Schornagel, A. Denis, M. Green, A. Iveson, M. Azab, I. Seymour for the Tomudex Colorectal Study Group: ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J. clin. Oncol. 14 (1996), 716–721.

    PubMed  CAS  Google Scholar 

  199. Zelefsky, M. J., S. A. Leibel, K. E. Wallner, W. F. Whitmore, Z. Fuks Jr: Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer. J. clin. Oncol. 13 (1995), 459–463.

    PubMed  CAS  Google Scholar 

  200. Zittoun, R. A., S. Suciu, F. Mandelli, T. de Witte, J. Thaler, P. Stryckmans, M. Hayat, M. Peetermans, M. Cadiou, G. Solbu, M. C. Petti, R. Willemze: Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J. clin. Oncol. 14 (1995), 2150–2159.

    Google Scholar 

  201. Zittoun, R. A., F. Mandelli, R. Willemze, T. De Witte, B. Labar, L. Resegotti, F. Leoni, E. Damasio, G. Visani, G. Papa, F. Caronia, M. Hayat, P. Stryckmans, B. Rotolli, P. Leoni, M. E. Peetermans, M. Dardenne, M. L. Vegna, M. C. Petti, G. Solbu, S. Suciu, for the European Organization for Research and Treatment of Cancer (EORTC) an the Gruppo Italiano Malattie Ematologiche Maligne Dell’Adulto (GIMEMA) Leukemia Cooperative Groups: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. New Engl. J. Med. 332 (1995), 217–223.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik, Innere Medizin I der Universität des Saarlandes, Homburg (Saar)

    Frank Hartmann & Michael Pfreundschuh

Authors
  1. Frank Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Pfreundschuh
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hartmann, F., Pfreundschuh, M. Onkologie ’96. Med. Klin. 92, 83–100 (1997). https://doi.org/10.1007/BF03042290

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03042290

Search

Navigation